Targeting memory processes with drugs to prevent or cure PTSD

Bibliography

• Friedman MJ, Resick PA, Bryant RA, Brewin CR. Considering ptsd for dsm-5. Depress Anxiety 2011;28(9):750-69
   PubMed Web of Science ®Google Scholar
• Friedman MJ, Resick PA, Bryant RA, Classification of trauma and stressor-related disorders in dsm-5. Depress Anxiety 2011;28(9):737-49
   PubMed Web of Science ®Google Scholar
• Foa EB. Psychosocial therapy for posttraumatic stress disorder. J Clin Psychiatry 2006;67(Suppl 2):40-5
   PubMed Web of Science ®Google Scholar
• Kowalik J, Weller J, Venter J, Drachman D. Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysis. J Behav Ther Exp Psychiatry 2011;42(3):405-13
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Lifetime prevalence and age-of-onset distributions of dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62(6):593-602
   PubMed Web of Science ®Google Scholar
• Brunello N, Davidson JR, Deahl M, Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001;43(3):150-62
   PubMed Web of Science ®Google Scholar
• Hoge CW, Castro CA, Messer SC, Combat duty in iraq and afghanistan, mental health problems and barriers to care. US Army Medical Department journal 2008;7-17
   PubMedGoogle Scholar
• McFarlane AC, Williamson P, Barton CA. The impact of traumatic stressors in civilian occupational settings. J Public Health Policy 2009;30(3):311-27
   PubMed Web of Science ®Google Scholar
• Ledford H. Neuroscientists unite for. ‘moon shot'. Nature 2011. doi:10.1038/news.2011.324
   Google Scholar
• Shalev AY. PTSD: A disorder of recovery? In: Kirmayer L, Lemelson R, Barad M, editors. Understanding trauma: integrating biological, clinical, and cultural perspectives. Cambridge University Press; New York, NY: 2007. p. 207-23
   Google Scholar
• Yehuda R. Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry 2004;65(Suppl 1):29-36
   PubMed Web of Science ®Google Scholar
• Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003;417:38-50
   PubMedGoogle Scholar
• Ressler KJ, Mercer KB, Bradley B, Post-traumatic stress disorder is associated with pacap and the pac1 receptor. Nature 2011;470(7335):492-7
   PubMed Web of Science ®Google Scholar
• Marmar CR, McCaslin SE, Metzler TJ, Predictors of posttraumatic stress in police and other first responders. Ann NY Acad Sci 2006(1071):1-18
   PubMedGoogle Scholar
• Heim C, Nemeroff CB. Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry 2002;7(2):147-59
   PubMedGoogle Scholar
• Nemeroff CB, Bremner JD, Foa EB, Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006;40(1):1-21
   PubMed Web of Science ®Google Scholar
• Yehuda R, LeDoux J. Response variation following trauma: a translational neuroscience approach to understanding ptsd. Neuron 2007;56(1):19-32
   PubMed Web of Science ®Google Scholar
• Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety 2009;26(11):984-92
   PubMed Web of Science ®Google Scholar
• Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annu Rev Clin Psychol 2005;1:255-91
   PubMed Web of Science ®Google Scholar
• Davis M, Barad M, Otto M, Southwick S. Combining pharmacotherapy with cognitive behavioral therapy: traditional and new approaches. J Trauma Stress 2006;19(5):571-81
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D. Pharmacotherapy treatment of ptsd and comorbid disorders. Psychiatr Danub 2009;21(3):411-14
   PubMed Web of Science ®Google Scholar
• Delahanty DL, Nugent NR. Predicting ptsd prospectively based on prior trauma history and immediate biological responses. Ann NY Acad Sci 2006;1071:27-40
   PubMed Web of Science ®Google Scholar
• Fanselow MS, Lester LS. A functional behavioristic approach to aversively motivated behavior: predatory imminence as a determinant of the topography of defensive behavior. In: Bolles RC, Beecher MD, editors. Evolution and learning. Hillsdale, NJ: Erlbaum; 1988. p. 185-211
   Google Scholar
• Blanchard DC, Yang M, Herbert M, Blanchard RJ. Defensive behaviors. In: Fink G, editor. Encyclopedia of stress. Oxford: Academic Press; 2007. p. 722-26
   Google Scholar
• Selye H. The stress of life. McGraw-Hill; New York: 1978
   Google Scholar
• Southwick SM, Bremner JD, Rasmusson A, Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999;46(9):1192-204
   PubMed Web of Science ®Google Scholar
• Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999;160(1):1-12
   PubMed Web of Science ®Google Scholar
• Kehne JH, Cain CK. Therapeutic utility of non-peptidic crf1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 2010;128(3):460-87
   PubMed Web of Science ®Google Scholar
• Kasckow JW, Baker D, Geracioti TD Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001;22(5):845-51
   PubMed Web of Science ®Google Scholar
• Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002;346(2):108-14
   PubMed Web of Science ®Google Scholar
• Karatsoreos IN, McEwen BS. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci 2011;15(12):576-84
   PubMed Web of Science ®Google Scholar
• Gale GD, Anagnostaras SG, Godsil BP, Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats. J Neurosci 2004;24(15):3810-15
   PubMed Web of Science ®Google Scholar
• LeDoux J. Rethinking the emotional brain. Neuron 2012;73(4):653-76
   PubMed Web of Science ®Google Scholar
• Maren S. Neurobiology of pavlovian fear conditioning. Annu Rev Neurosci 2001;24:897-931
   PubMed Web of Science ®Google Scholar
• Rodrigues SM, Schafe GE, LeDoux JE. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 2004;44(1):75-91
   PubMed Web of Science ®Google Scholar
• Johansen JP, Cain CK, Ostroff LE, LeDoux JE. Molecular mechanisms of fear learning and memory. Cell 2011;147(3):509-24
   PubMed Web of Science ®Google Scholar
• Cain CK, LeDoux JE, In: Nutt DJ, Blanchard RJ, Blanchard DC, Griebel G, editors. Handbook of anxiety and fear 17. Elsevier Academic Press; Amsterdam: 2008. p. 103-25
   Google Scholar
• Sigurdsson T, Doyere V, Cain CK, LeDoux JE. Long-term potentiation in the amygdala: a cellular mechanism of fear learning and memory. Neuropharmacology 2007;52(1):215-27
   PubMed Web of Science ®Google Scholar
• Rumpel S, LeDoux J, Zador A, Malinow R. Postsynaptic receptor trafficking underlying a form of associative learning. Science 2005;308(5718):83-8
   PubMed Web of Science ®Google Scholar
• Balleine BW, Killcross S. Parallel incentive processing: an integrated view of amygdala function. Trends Neurosci 2006;29(5):272-9
   PubMed Web of Science ®Google Scholar
• Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: Ten years of progress. Annual review of psychology 2012;63:129-51
   PubMed Web of Science ®Google Scholar
• Josselyn SA. Continuing the search for the engram: examining the mechanism of fear memories. J Psychiatry Neurosci 2010;35(4):221-8
   PubMed Web of Science ®Google Scholar
• Sacktor TC. How does pkmzeta maintain long-term memory? Nat Rev Neurosci 2011;12(1):9-15
   PubMed Web of Science ®Google Scholar
• Parsons RG, Davis M. Temporary disruption of fear-potentiated startle following pkmzeta inhibition in the amygdala. Nat Neurosci 2011;14(3):295-6
   PubMed Web of Science ®Google Scholar
• Sara SJ. Retrieval and reconsolidation: toward a neurobiology of remembering. Learn Mem 2000;7(2):73-84
   PubMed Web of Science ®Google Scholar
• Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000;406(6797):722-6
   PubMed Web of Science ®Google Scholar
• Suzuki A, Josselyn SA, Frankland PW, Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 2004;24(20):4787-95
   PubMed Web of Science ®Google Scholar
• Cain CK, Debiec J, LeDoux JE. Consolidation and reconsolidation of pavlovian fear conditioning: roles for intracellular signaling and extracellular modulation in memory storage. In: Fields R, editor. Beyond the synapse: cell-cell signaling in synaptic plasticit. Cambridge University Press; New York, NY: 2008. p. 72-88
   Google Scholar
• Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 2006;26(39):10051-6
   PubMed Web of Science ®Google Scholar
• Schiller D, Monfils MH, Raio CM, Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010;463(7277):49-53
   PubMed Web of Science ®Google Scholar
• Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron 2002;36(4):567-84
   PubMed Web of Science ®Google Scholar
• Pickens CL, Golden SA, Adams-Deutsch T, Long-lasting incubation of conditioned fear in rats. Biol Psychiatry 2009;65(10):881-6
   PubMed Web of Science ®Google Scholar
• Eysenck HJ. A theory of the incubation of anxiety-fear responses. Behav Res Ther 1968;6(3):309-21
   PubMed Web of Science ®Google Scholar
• Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats–a possible mechanism for the persistence of traumatic memories in ptsd. Depress Anxiety 2011;28(3):186-93
   PubMed Web of Science ®Google Scholar
• Bouton ME, Westbrook RF, Corcoran KA, Maren S. Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol Psychiatry 2006;60(4):352-60
   PubMed Web of Science ®Google Scholar
• Likhtik E, Popa D, Apergis-Schoute J, Amygdala intercalated neurons are required for expression of fear extinction. Nature 2008;454(7204):642-5
   PubMed Web of Science ®Google Scholar
• McNally GP, Pigg M, Weidemann G. Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning. J Neurosci 2004;24(31):6912-19
   PubMed Web of Science ®Google Scholar
• Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002;420(6911):70-4
   PubMed Web of Science ®Google Scholar
• Ji J, Maren S. Hippocampal involvement in contextual modulation of fear extinction. Hippocampus 2007;17(9):749-58
   PubMed Web of Science ®Google Scholar
• Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007;12(2):120-50
   PubMed Web of Science ®Google Scholar
• Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 2010;90(2):419-63
   PubMed Web of Science ®Google Scholar
• Ostroff LE, Cain CK, Bedont J, Fear and safety learning differentially affect synapse size and dendritic translation in the lateral amygdala. Proc Natl Acad Sci USA 2010;107(20):9418-23
   PubMed Web of Science ®Google Scholar
• Cain CK, LeDoux JE. Escape from fear: a detailed behavioral analysis of two atypical responses reinforced by cs termination. J Exp Psychol Anim Behav Process 2007;33(4):451-63
   PubMed Web of Science ®Google Scholar
• Lazaro-Munoz G, LeDoux JE, Cain CK. Sidman instrumental avoidance initially depends on lateral and basal amygdala and is constrained by central amygdala-mediated pavlovian processes. Biol Psychiatry 2010;67(12):1120-7
   PubMed Web of Science ®Google Scholar
• Ferry B, Roozendaal B, McGaugh JL. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry 1999;46(9):1140-52
   PubMed Web of Science ®Google Scholar
• Bush DE, Sotres-Bayon F, LeDoux JE. Individual differences in fear: isolating fear reactivity and fear recovery phenotypes. J Trauma Stress 2007;20(4):413-22
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Morinobu S, Takei S, Single prolonged stress: toward an animal model of posttraumatic stress disorder. Depress Anxiety 2009;26(12):1110-17
   PubMed Web of Science ®Google Scholar
• Rau V, DeCola JP, Fanselow MS. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev 2005;29(8):1207-23
   PubMed Web of Science ®Google Scholar
• Roozendaal B, McEwen BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci 2009;10(6):423-33
   PubMed Web of Science ®Google Scholar
• Yehuda R, Koenen KC, Galea S, Flory JD. The role of genes in defining a molecular biology of ptsd. Dis Markers 2011;30(2-3):67-76
   PubMed Web of Science ®Google Scholar
• Baker DG, Nievergelt CM, O'Connor DT. Biomarkers of ptsd: neuropeptides and immune signaling. Neuropharmacology 2012;62(2):663-73
   PubMed Web of Science ®Google Scholar
• Skelton K, Ressler KJ, Norrholm SD, Ptsd and gene variants: new pathways and new thinking. Neuropharmacology 2012;62(2):628-37
   PubMed Web of Science ®Google Scholar
• Jovanovic T, Norrholm SD, Blanding NQ, Impaired fear inhibition is a biomarker of ptsd but not depression. Depress Anxiety 2010;27(3):244-51
   PubMed Web of Science ®Google Scholar
• Milad MR, Pitman RK, Ellis CB, Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 2009;66(12):1075-82
   PubMed Web of Science ®Google Scholar
• Jovanovic T, Norrholm SD, Fennell JE, Posttraumatic stress disorder may be associated with impaired fear inhibition: Relation to symptom severity. Psychiatry Res 2009;167(1-2):151-60
   PubMed Web of Science ®Google Scholar
• Grillon C, Morgan CA III. Fear-potentiated startle conditioning to explicit and contextual cues in gulf war veterans with posttraumatic stress disorder. J Abnorm Psychol 1999;108(1):134-42
   PubMed Web of Science ®Google Scholar
• Orr SP, Metzger LJ, Lasko NB, De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000;109(2):290-8
   PubMed Web of Science ®Google Scholar
• Jovanovic T, Ressler KJ. How the neurocircuitry and genetics of fear inhibition may inform our understanding of ptsd. Am J Psychiatry 2010;167(6):648-62
   PubMed Web of Science ®Google Scholar
• Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. J Neurosci 2000;20(16):6225-31
   PubMed Web of Science ®Google Scholar
• Pitman RK, Delahanty DL. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr 2005;10(2):99-106
   PubMed Web of Science ®Google Scholar
• Quirk GJ. Learning not to fear, faster. Learn Mem 2004;11(2):125-6
   PubMed Web of Science ®Google Scholar
• Golub Y, Mauch CP, Dahlhoff M, Wotjak CT. Consequences of extinction training on associative and non-associative fear in a mouse model of posttraumatic stress disorder (ptsd). Behav Brain Res 2009;205(2):544-9
   PubMed Web of Science ®Google Scholar
• Casada JH, Amdur R, Larsen R, Liberzon I. Psychophysiologic responsivity in posttraumatic stress disorder: generalized hyperresponsiveness versus trauma specificity. Biol Psychiatry 1998;44(10):1037-44
   PubMed Web of Science ®Google Scholar
• van der Kolk BA. Clinical implications of neuroscience research in ptsd. Ann N Y Acad Sci 2006;1071:277-93
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Treatment of posttraumatic stress disorder: An assessment of the evidence. Press Release 2008
   Google Scholar
• Sharpless BA, Barber JP. A clinician's guide to ptsd treatments for returning veterans. Prof Psychol Res Pr 2011;42(1):8-15
   PubMed Web of Science ®Google Scholar
• Cukor J, Olden M, Lee F, Difede J. Evidence-based treatments for ptsd, new directions, and special challenges. Ann N Y Acad Sci 2010;1208:82-9
   PubMed Web of Science ®Google Scholar
• Choi DC, Rothbaum BO, Gerardi M, Ressler KJ. Pharmacological enhancement of behavioral therapy: Focus on posttraumatic stress disorder. Curr Top Behav Neurosci 2010;2:279-99
   PubMedGoogle Scholar
• Bouton ME, Kenney FA, Rosengard C. State-dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience 1990;104:44-55
   PubMed Web of Science ®Google Scholar
• Pratchett LC, Daly K, Bierer LM, Yehuda R. New approaches to combining pharmacotherapy and psychotherapy for posttraumatic stress disorder. Expert Opin Pharmacother 2011;12(15):2339-54
   PubMed Web of Science ®Google Scholar
• Ravindran LN, Stein MB. Pharmacotherapy of post-traumatic stress disorder. Curr Top Behav Neurosci 2010;2:505-25
   PubMedGoogle Scholar
• Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent ptsd: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007;20(6):923-32
   PubMed Web of Science ®Google Scholar
• Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2000;4:CD002795
   PubMedGoogle Scholar
• Post-traumatic stress disorder: the management of ptsd in adults and children in primary and secondary care. British Psychological Society; London: 2005
   Google Scholar
• Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 2009;14(1 Suppl 1):25-31
   PubMed Web of Science ®Google Scholar
• Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. S Afr Med J 2006;96(10):1088-96
   PubMed Web of Science ®Google Scholar
• Ursano RJ, Bell C, Eth S, Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004;161(11 Suppl):3-31
   PubMedGoogle Scholar
• Londborg PD, Hegel MT, Goldstein S, Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001;62(5):325-31
   PubMed Web of Science ®Google Scholar
• Karpova NN, Pickenhagen A, Lindholm J, Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011;334(6063):1731-4
   PubMed Web of Science ®Google Scholar
• Schneier FR, Neria Y, Pavlicova M, Combined prolonged exposure therapy and paroxetine for ptsd related to the world trade center attack: a randomized controlled trial. Am J Psychiatry 2012;169(1):80-8
   PubMed Web of Science ®Google Scholar
• Wang W, Liu Y, Zheng H, A modified single-prolonged stress model for post-traumatic stress disorder. Neurosci Lett 2008;441(2):237-41
   PubMed Web of Science ®Google Scholar
• Inoue T, Kitaichi Y, Koyama T. Ssris and conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(8):1810-19
   PubMed Web of Science ®Google Scholar
• Davidson J, Baldwin D, Stein DJ, Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006;63(10):1158-65
   PubMed Web of Science ®Google Scholar
• Davidson J, Rothbaum BO, Tucker P, Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006;26(3):259-67
   PubMed Web of Science ®Google Scholar
• Yang CH, Shi HS, Zhu WL, Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear. Behav Brain Res 2012;230(1):268-73
   PubMed Web of Science ®Google Scholar
• U.S. Departments of Veterans Affairs and Defense. Clinical Practice Guideline for the Management of Post-Traumatic Stress; 2010
   Google Scholar
• Klemenhagen KC, Gordon JA, David DJ, Increased fear response to contextual cues in mice lacking the 5-ht1a receptor. Neuropsychopharmacology 2006;31(1):101-11
   PubMed Web of Science ®Google Scholar
• Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry 1994;6(1):33-7
   PubMedGoogle Scholar
• Wells BG, Chu CC, Johnson R, Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy 1991;11(4):340-3
   PubMed Web of Science ®Google Scholar
• LaPorta LD, Ware MR. Buspirone in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1992;12(2):133-4
   PubMed Web of Science ®Google Scholar
• Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of ptsd. Depress Anxiety 1997;5(3):137-9
   PubMedGoogle Scholar
• Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1a receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 2004;504(1-2):65-77
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang ZJ, Zhang S, 5-ht2a receptor antagonism by mdl 11,939 during inescapable stress prevents subsequent exaggeration of acoustic startle response and reduced body weight in rats. J Psychopharmacol 2011;25(2):289-97
   PubMedGoogle Scholar
• Davis LL, Jewell ME, Ambrose S, A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol 2004;24(3):291-7
   PubMed Web of Science ®Google Scholar
• Davidson JR, Weisler RH, Butterfield MI, Mirtazapine vs. Placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53(2):188-91
   PubMed Web of Science ®Google Scholar
• Kakui N, Yokoyama F, Yamauchi M, Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: functional significance of 5-hydroxytryptamine 1a receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009;92(3):393-8
   PubMed Web of Science ®Google Scholar
• Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011;115(3):279-92
   PubMed Web of Science ®Google Scholar
• Sessa B. Is there a case for mdma-assisted psychotherapy in the uk? J Psychopharmacol 2007;21(2):220-4
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011;25(4):439-52
   PubMed Web of Science ®Google Scholar
• den Hollander B, Schouw M, Groot P, Preliminary evidence of hippocampal damage in chronic users of ecstasy. J Neurol Neurosurg Psychiatry 2012;83(1):83-5
   PubMed Web of Science ®Google Scholar
• Taylor FB, Martin P, Thompson C, Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008;63(6):629-32
   PubMed Web of Science ®Google Scholar
• Raskind MA, Thompson C, Petrie EC, Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry 2002;63(7):565-8
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Hoff DJ, A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61(8):928-34
   PubMed Web of Science ®Google Scholar
• Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol 2003;16(3):165-71
   PubMed Web of Science ®Google Scholar
• Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010;30(3):225-9
   PubMed Web of Science ®Google Scholar
• Taylor FB, Lowe K, Thompson C, Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry 2006;59(7):577-81
   PubMed Web of Science ®Google Scholar
• Boynton L, Bentley J, Strachan E, Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population. J Psychiatr Pract 2009;15(6):454-9
   PubMed Web of Science ®Google Scholar
• Bernardi RE, Lattal KM. A role for alpha-adrenergic receptors in extinction of conditioned fear and cocaine conditioned place preference. Behav Neurosci 2010;124(2):204-10
   PubMed Web of Science ®Google Scholar
• Lazzaro SC, Cain CK, Cunha C, LeDoux JE. Terazosin, an alpha1 adrenergic receptor antagonist, enhances acquisition and impairs extinction, but does not affect consolidation of pavlovian cue fear. Soc Neurosci Abstr 2009;479:22
   Google Scholar
• Reist C, Duffy JG, Fujimoto K, Cahill L. Beta-adrenergic blockade and emotional memory in ptsd. Int J Neuropsychopharmacol 2001;4(4):377-83
   PubMed Web of Science ®Google Scholar
• Pitman RK, Sanders KM, Zusman RM, Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51(2):189-92
   PubMed Web of Science ®Google Scholar
• Vaiva G, Ducrocq F, Jezequel K, Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003;54(9):947-9
   PubMed Web of Science ®Google Scholar
• Nugent NR, Christopher NC, Crow JP, The efficacy of early propranolol administration at reducing ptsd symptoms in pediatric injury patients: a pilot study. J Trauma Stress 2010;23(2):282-7
   PubMed Web of Science ®Google Scholar
• Hoge EA, Worthington JJ, Nagurney JT, Effect of acute posttrauma propranolol on ptsd outcome and physiological responses during script-driven imagery. CNS Neurosci Ther 2012;18(1):21-7
   PubMed Web of Science ®Google Scholar
• McGaugh JL, McIntyre CK, Power AE. Amygdala modulation of memory consolidation: interaction with other brain systems. Neurobiol Learn Mem 2002;78(3):539-52
   PubMed Web of Science ®Google Scholar
• Debiec J, LeDoux JE. Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience 2004;129(2):267-72
   PubMed Web of Science ®Google Scholar
• Bush DE, Caparosa EM, Gekker A, Ledoux J. Beta-adrenergic receptors in the lateral nucleus of the amygdala contribute to the acquisition but. not the consolidation of auditory fear conditioning. Front Behav Neurosci 2010;4:154
   PubMedGoogle Scholar
• Brunet A, Orr SP, Tremblay J, Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42(6):503-6
   PubMed Web of Science ®Google Scholar
• Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci 2009;12(3):256-8
   PubMed Web of Science ®Google Scholar
• Schiller D, Phelps EA. Does reconsolidation occur in humans? Front Behav Neurosci 2011;5:24
   PubMedGoogle Scholar
• Mueller D, Porter JT, Quirk GJ. Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 2008;28(2):369-75
   PubMed Web of Science ®Google Scholar
• Soeter M, Kindt M. Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. Neuropsychopharmacology 2012;37(5):1204-15
   PubMed Web of Science ®Google Scholar
• Cain CK, Blouin AM, Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 2004;11(2):179-87
   PubMed Web of Science ®Google Scholar
• Morris RW, Bouton ME. The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 2007;121(3):501-14
   PubMed Web of Science ®Google Scholar
• Powers MB, Smits JA, Otto MW, Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009;23(3):350-6
   PubMed Web of Science ®Google Scholar
• Hefner K, Whittle N, Juhasz J, Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 2008;28(32):8074-85
   PubMed Web of Science ®Google Scholar
• Rudy JW, Kuwagama K, Pugh CR. Isolation reduces contextual but not auditory-cue fear conditioning: a role for endogenous opioids. Behav Neurosci 1999;113(2):316-23
   PubMed Web of Science ®Google Scholar
• Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002;22(6):2343-51
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Kremer I, Javitt DC, Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002;5(4):301-7
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Shimoni J, Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002;159(3):480-2
   PubMed Web of Science ®Google Scholar
• Aerni A, Traber R, Hock C, Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 2004;161(8):1488-90
   PubMed Web of Science ®Google Scholar
• Jovanovic T, Phifer JE, Sicking K, Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 2011;36(10):1540-52
   PubMed Web of Science ®Google Scholar
• Miller MW, McKinney AE, Kanter FS, Hydrocortisone suppression of the fear-potentiated startle response and posttraumatic stress disorder. Psychoneuroendocrinology 2011;36(7):970-80
   PubMed Web of Science ®Google Scholar
• Weis F, Kilger E, Roozendaal B, Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study. J Thorac Cardiovasc Surg 2006;131(2):277-82
   PubMed Web of Science ®Google Scholar
• Schelling G, Kilger E, Roozendaal B, Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 2004;55(6):627-33
   PubMed Web of Science ®Google Scholar
• Schelling G, Briegel J, Roozendaal B, The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry 2001;50(12):978-85
   PubMed Web of Science ®Google Scholar
• Suris A, North C, Adinoff B, Effects of exogenous glucocorticoid on combat-related ptsd symptoms. Ann Clin Psychiatry 2010;22(4):274-9
   PubMed Web of Science ®Google Scholar
• Kehne JH, Cain CK. Therapeutic utility of non-peptidic crf(1) receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 2010
   PubMed Web of Science ®Google Scholar
• Deak T, Nguyen KT, Ehrlich AL, The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999;140(1):79-86
   PubMed Web of Science ®Google Scholar
• Yang YL, Chao PK, Ro LS, Glutamate nmda receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 2007;32(5):1042-51
   PubMed Web of Science ®Google Scholar
• Bernardy NC, Lund BC, Alexander B, Friedman MJ. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry 2012;73(3):297-303
   PubMed Web of Science ®Google Scholar
• Hartley CA, Phelps EA. Changing fear: the neurocircuitry of emotion regulation. Neuropsychopharmacology 2010;35(1):136-46
   PubMed Web of Science ®Google Scholar
• Walderhaug E, Kasserman S, Aikins D, Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry 2010;43(2):45-9
   PubMed Web of Science ®Google Scholar
• Villarreal G, Canive JM, Calais LA, Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull 2010;43(3):26-34
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Kanter ED, Reduction of nightmares and other ptsd symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160(2):371-3
   PubMed Web of Science ®Google Scholar
• Davis LL, Ward C, Rasmusson A, A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008;41(1):8-18
   PubMed Web of Science ®Google Scholar
• Neylan TC, Lenoci M, Samuelson KW, No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006;163(12):2186-8
   PubMed Web of Science ®Google Scholar
• Kinzie JD, Leung P. Clonidine in cambodian patients with posttraumatic stress disorder [see comments]. J Nerv Ment Dis 1989;177(9):546-50
   PubMed Web of Science ®Google Scholar
• Becker ME, Hertzberg MA, Moore SD, A placebo-controlled trial of bupropion sr in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(2):193-7
   PubMed Web of Science ®Google Scholar
• Krystal JH, Rosenheck RA, Cramer JA, Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related ptsd: a randomized trial. JAMA 2011;306(5):493-502
   PubMed Web of Science ®Google Scholar
• Rothbaum BO, Killeen TK, Davidson JR, Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008;69(4):520-5
   PubMed Web of Science ®Google Scholar
• Padala PR, Madison J, Monnahan M, Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006;21(5):275-80
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry 2005;66(7):922-7
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Lu PH, Turner J, Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57(5):474-9
   PubMed Web of Science ®Google Scholar
• Reich DB, Winternitz S, Hennen J, A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004;65(12):1601-6
   PubMed Web of Science ®Google Scholar
• David D, De Faria L, Lapeyra O, Mellman TA. Adjunctive risperidone treatment in combat veterans with chronic ptsd. J Clin Psychopharmacol 2004;24(5):556-9
   PubMed Web of Science ®Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003;23(2):193-6
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol 2007;10(2):253-61
   PubMed Web of Science ®Google Scholar
• Ahearn EP, Mussey M, Johnson C, Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol 2006;21(1):29-33
   PubMed Web of Science ®Google Scholar
• Robert S, Hamner MB, Kose S, Quetiapine improves sleep disturbances in combat veterans with ptsd: sleep data from a prospective, open-label study. J Clin Psychopharmacol 2005;25(4):387-8
   PubMed Web of Science ®Google Scholar
• Hamner MB, Deitsch SE, Brodrick PS, Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23(1):15-20
   PubMed Web of Science ®Google Scholar
• Davidson J, Kudler H, Smith R, Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990;47(3):259-66
   PubMed Web of Science ®Google Scholar
• Frank JB, Kosten TR, Giller EL Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988;145(10):1289-91
   PubMed Web of Science ®Google Scholar
• Kosten TR, Frank JB, Dan E, Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991;179(6):366-70
   PubMed Web of Science ®Google Scholar
• Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl) 2004;175(4):451-6
   PubMed Web of Science ®Google Scholar
• Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for ssri-resistant combat-related ptsd: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159(10):1777-9
   PubMed Web of Science ®Google Scholar
• Petty F, Brannan S, Casada J, Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001;16(6):331-7
   PubMed Web of Science ®Google Scholar
• Butterfield MI, Becker ME, Connor KM, Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001;16(4):197-203
   PubMed Web of Science ®Google Scholar
• Robert S, Hamner MB, Durkalski VL, An open-label assessment of aripiprazole in the treatment of ptsd. Psychopharmacol Bull 2009;42(1):69-80
   PubMed Web of Science ®Google Scholar
• Mello MF, Costa MC, Schoedl AF, Fiks JP. Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr 2008;30(4):358-61
   PubMed Web of Science ®Google Scholar
• Villarreal G, Calais LA, Canive JM, Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull 2007;40(2):6-18
   PubMed Web of Science ®Google Scholar
• Holbrook TL, Galarneau MR, Dye JL, Morphine use after combat injury in iraq and post-traumatic stress disorder. N Engl J Med 2010;362(2):110-17
   PubMed Web of Science ®Google Scholar
• Bryant RA, Creamer M, O'Donnell M, A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009;65(5):438-40
   PubMed Web of Science ®Google Scholar
• Stoddard FJ Jr, Sorrentino EA, Ceranoglu TA, Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burns. J Burn Care Res 2009;30(5):836-43
   PubMed Web of Science ®Google Scholar
• Saxe G, Stoddard F, Courtney D, Relationship between acute morphine and the course of ptsd in children with burns. J Am Acad Child Adolesc Psychiatry 2001;40(8):915-21
   PubMed Web of Science ®Google Scholar
• Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci 1993;30(4):255-63
   PubMed Web of Science ®Google Scholar
• Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol 2002;17(4):181-5
   PubMed Web of Science ®Google Scholar
• Henn-Haase HC, Best BS, Metzler MT, Exposure based cbt therapy and d-cycloserine treatment for ptsd in veterans and civilians. 2010
   Google Scholar
• Guay GS, Marchand MA, Landry LP. Results from a six-month follow-up of a randomized controlled trial assessing the efficacy of cognitive-behavior therapy combined with d-cycloserine for treating ptsd. 2010
   Google Scholar
• Schonenberg M, Reichwald U, Domes G, Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol 2008;22(5):493-7
   PubMed Web of Science ®Google Scholar
• McGhee LL, Maani CV, Garza TH, The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 2008;64(2 Suppl):S195-8; Discussion S197-198
   PubMed Web of Science ®Google Scholar
• Tucker P, Trautman RP, Wyatt DB, Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(2):201-6
   PubMed Web of Science ®Google Scholar
• Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(6):677-81
   PubMed Web of Science ®Google Scholar
• Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002;63(1):15-20
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Butterfield MI, Feldman ME, A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45(9):1226-9
   PubMed Web of Science ®Google Scholar
• Davidson JR, Brady K, Mellman TA, The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27(1):85-8
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR, Weisler RH, Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl) 2006;184(1):21-5
   PubMed Web of Science ®Google Scholar
• Davis LL, Davidson JR, Ward LC, Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008;28(1):84-8
   PubMed Web of Science ®Google Scholar
• Hamner MB, Brodrick PS, Labbate LA. Gabapentin in ptsd: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001;13(3):141-6
   PubMedGoogle Scholar
• Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67(2):211-14
   PubMed Web of Science ®Google Scholar
• Pollack MH, Hoge EA, Worthington JJ, Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(7):892-7
   PubMed Web of Science ®Google Scholar
• Gelpin E, Bonne O, Peri T, Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996;57(9):390-4
   PubMed Web of Science ®Google Scholar
• Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51(6):236-8
   PubMed Web of Science ®Google Scholar
• Cates ME, Bishop MH, Davis LL, Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother 2004;38(9):1395-9
   PubMed Web of Science ®Google Scholar
• Mellman TA, Bustamante V, David D, Fins AI. Hypnotic medication in the aftermath of trauma. J Clin Psychiatry 2002;63(12):1183-4
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Vythilingam M, Murrough JW, A selective neurokinin-1 receptor antagonist in chronic ptsd: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011;21(3):221-9
   PubMed Web of Science ®Google Scholar
• Kehne JH. The crf1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007;6(3):163-82
   PubMedGoogle Scholar